drugset
drugset / Trial / NCT03829345

A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer

NCT03829345 ↗

Phase 2 Unknown 54 enrolled Royal Marsden NHS Foundation Trust AstraZeneca · collab
NaSingle-groupOpen-labelTreatment

Summary

SOlar is a multi-centre phase II clinical trial of single agent olaparib in advanced oesophagogastric cancer.

Timeline

Start
2019-07-02
Primary completion
2021-02-14
Completion
2022-02-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Olaparib Small molecule 300 mg Oral

Indications

esophageal cancer gastric cancer gastroesophageal cancer